Related Experiment Video
Updated: Jul 2, 2025
11:47
Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
Published on: January 22, 2017
10.6K
Recent advances in non-Huntington's disease choreas
Molly C Cincotta1, Ruth H Walker2
1Department of Neurology, Temple University, Philadelphia, PA, USA.
Parkinsonism & Related Disorders
|February 20, 2024
Summary
Recent literature reveals new causes of chorea, including autoimmune, metabolic, and genetic factors. Advances in understanding pathophysiology and therapeutics offer hope for this basal ganglia disorder.
Area of Science:
- Neurology
- Movement Disorders
- Neuroscience
Background:
- Chorea stems from basal ganglia output pathway imbalances, often linked to caudate nucleus and putamen dysfunction.
- Numerous underlying causes contribute to chorea, necessitating comprehensive diagnostic approaches.
Purpose of the Study:
- To review recent literature identifying novel causes of chorea.
- To explore advancements in understanding the pathophysiology and treatment of chorea.
Main Methods:
- Literature review focusing on autoimmune, metabolic, and genetic etiologies of chorea.
- Analysis of recent findings on chorea mechanisms and therapeutic developments.
Main Results:
- Newly identified autoantibodies are recognized causes of chorea.
- COVID-19 infection and vaccination are rarely associated with chorea; causality requires further investigation.
- Genetic testing advances reveal more chorea causes and expand known genetic disorder phenotypes.
- Deep brain stimulation shows potential therapeutic success in specific chorea cases.
Conclusions:
- Understanding of chorea pathophysiology is progressing.
- Further research is essential to fully elucidate the mechanisms and treatment of this movement disorder.
Related Concept Videos
01:15Parkinson's Disease: Overview
546
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
546
01:24Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
01:22Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K